Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Early data has indicated that EGFR 19Del mutation and EGFR L585R mutation are two different types of non‐small cell lung cancer (NSCLC). However, how the different molecular mechanisms participate in the process of mediastinal lymph node metastasis (MLNM) in lung adenocarcinoma (LA) harboring EGFR 19Del and EGFR L858R mutation remains unknown. We thus explored the genes responsible for MLNM in LA with EGFR 19Del or L858R mutation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We performed transcriptome sequencing and bioinformatics analysis from 10 patients with LA resection specimens of primary tumors. Quantitative reverse transcription‐polymerase chain reaction was used to validate gene expressions.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>There were 69 mRNAs upregulated and 100 mRNAs downregulated in five samples with MLNM compared with samples without MLN metastasis. EEF1A2 and ERN2 were observed exhibiting different expression patterns in EGFR 19Del and EGFR L858R samples with MLNM. In samples harboring EGFR 19Del mutation, the expression of EEF1A2 gene in samples with MLNM was significantly lower compared with samples without MLN metastasis, and in samples with EGFR L858R, it was significantly higher in samples with MLNM. The expression pattern of ERN2 was opposite to EEF1A2. In addition, several other genes including SLC6A11, IGHV3‐48, IGHV3‐43, DUSP9, and HOXA9 were also shown to be associated with invasion and metastasis and exhibited an expression pattern similar to EEF1A2 and ERN2 in EGRF 19Del and L858R mutation tumors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>EEF1A2 and ERN2 were for the first time observed exhibiting distinct expression patterns in MLNM in lung adenocarcinomas harboring EGFR 19Del and EGFR L858R mutation by interindividual DEGs analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3><p><b>Significant findings of the study</b></p><p>In our study, we focused on the mechanisms of metastasis and invasion that different EGFR mutations conferred and identified two critical genes separately involved in this process in EGFR 19Del and L858R mutation tumors.</p><p><b>What this study adds</b></p><p>Our findings not only reinforced theoretical foundations that the EGFR 19Del and L858R mutation tumors should be considered as two kinds of diseases, but also laid the fundamentals for precise determination of the mediastinal lymph node radiation field and improvement of clinical outcome.</p></section>

Silencing of lncRNA LOC105376794 promotes migration, invasion, and Gefitinib resistance of lung adenocarcinoma cells with EGFR 19Del mutation by ATF4/CHOP axis and ERK phosphorylation

Long Non-Coding RNA BC087858 Induces Non-T790m Mutation Acquired Resistance to EGFR-TKIs by Activating PI3K/AKT and MEK/ERK Pathways and EMT in Non-Small-cell Lung Cancer

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Microarray Expression Profile of Long Non-Coding Rnas in Egfr-Tkis Resistance of Human Non-Small Cell Lung Cancer

Different Stories for Different EGFR Exon 19 Deletion Variants

Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma

C-MYC inducible onco-lncRNA LINC00036 acting as EGFR mRNA stabilizer via RNA-protein and RNA-RNA interactions decreases the sensitivity of gefitinib in human cancer

Tumor‑released Lncrna H19 Promotes Gefitinib Resistance Via Packaging into Exosomes in Non‑small Cell Lung Cancer

β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy

Plasma MiRNA Alterations Between NSCLC Patients Harboring Del19 and L858R EGFR Mutations.

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer

LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis

Transcriptome Analysis of EGFR Tyrosine Kinase Inhibitors Resistance Associated Long Noncoding RNA in Non-Small Cell Lung Cancer.

EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del / L858R mutations

P3.02b-041 Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: EGFR Biomarkers

LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers

LncRNA LOC105372579 promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma via activating miR-4316/FOXP4 signaling

Identification and Verification of a Prognostic Ferroptosis-Related Lncrnas Signature for Patients with Lung Adenocarcinoma.

LOC441178 Overexpression Inhibits the Proliferation and Migration of Esophageal Carcinoma Cells via Methylation of miR-182

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and Its Subtypes in Lung Adenocarcinoma

PS01.80: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: Medical Oncology.